- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Study Finds New Evidence on Personalized Selection of Antiplatelet Therapy
Oral P2Y12 inhibitors (clopidogrel, prasugrel, and ticagrelor) used in conjunction with aspirin constitute a key strategy for the prevention of ischaemic recurrences in patients with the acute coronary syndrome (ACS). However, a recent study suggests compared with a standard selection of potent P2Y12 inhibitors, a guided selection of P2Y12 inhibiting therapy using platelet function or genetic testing improves outcomes without any significant trade-off in bleeding. The study findings were published in the European Heart Journal on December 16, 2021.
The guidelines recommend the use of P2Y12 inhibitors than clopidogrel to reduce ischemic events in ACS patients. However, this comes at the cost of increased bleeding. Comprehensive comparative analysis that provides safety and efficacy of currently recommended oral P2Y12 inhibitor strategies, including a guided selection approach using platelet function or genetic testing may provide important insights on the best treatment to be used in the specific setting of ACS. Therefore, Dr Mattia Galli and his team conducted a study to evaluate the comparative safety and efficacy of guided vs routine selection of potent P2Y12 inhibiting therapy in patients with ACS.
In a network meta-analysis, the researchers included 61,898 patients from 15 randomized trials that compared different oral P2Y12 inhibitors for the treatment of ACS using either a guided or standard selection approach. They determined clopidogrel as a reference treatment. The major efficacy endpoint assessed was the incidence of major adverse cardiovascular events (MACE) and the major safety endpoint was the incidence of all bleeding.
Key findings of the study:
- Over a mean follow up of 11.9 months, the researchers found that only individualized treatment was associated with a reduction in MACE (incidence rate ratio [IRR] 0.80) without any increase in bleeding (IRR 1.22).
- They noted both a guided approach and prescribing prasugrel led to a decrease in myocardial infarction, while a guided approach and prescribing either prasugrel or ticagrelor were all linked with reduced stent thrombosis.
- They observed that total and cardiovascular mortality were lower with ticagrelor.
- However, they noted that prasugrel was associated with increased major bleeding and minor bleeding went up with both prasugrel and ticagrelor.
The authors concluded, "In patients with an ACS, compared with a routine selection of potent P2Y12 inhibiting therapy (prasugrel or ticagrelor), a guided selection of P2Y12 inhibiting therapy is associated with the most favourable balance between safety and efficacy. These findings support broader adoption of guided approach for the selection of P2Y12 inhibiting therapy in patients with ACS."
For further information:
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751